Here's How Moderna Could Top $450 Again

Here's How Moderna Could Top $450 Again

Moderna (NASDAQ: MRNA) shares have dropped 70% since their record high of more than $450 last August. The second reason has to do with Moderna specifically. The company's only commercialized product right now is the coronavirus vaccine, so investors worry about earnings if vaccine demand drops in a post-pandemic world.